Weight loss
Cagrilintide, simplified.
Also called Long-acting amylin analog; half of CagriSema
Human studiesA lab-made copy of amylin, a fullness hormone released with insulin. It is being tested alone and paired with semaglutide as "CagriSema".
- Size
- 37 amino acids + fatty acid
- How it is taken
- Weekly injection (in trials)
- Status
- Investigational, not approved
- Available sizes
- Vials: 5 mg, 10 mg
What is it?
Your pancreas releases amylin alongside insulin after meals. It tells the brain you are full and slows the stomach. Cagrilintide is a long-acting version, and it works on a different signal than GLP-1, which is why it is being combined with semaglutide.
Got a vial? See how it mixes
Tap your vial size to watch how it is mixed and see exactly what each mark on the syringe holds.
What studies show
- In peopleIn a 26-week trial, the top dose on its own led to about 10.8% weight loss, compared with about 3% on placebo.
- In peopleCombined with semaglutide (CagriSema), people in a 68-week trial lost about 20% of their body weight on average.
What we don’t know yet
- Long-term safety, since it is still in trials.
- Whether it will be approved on its own or only as part of CagriSema.
Side effects and cautions
- Nausea and other stomach side effects, similar to GLP-1 drugs.
- Research-grade products are not the tested drug and have no quality control.
Is it legal?
Not FDA-approved as of our last review. Available only inside clinical trials.
Dosage & schedule evidence
How to read published schedules
Third-party schedules are not established clinical dosing standards. Human dose, frequency, and long-term safety may be unknown.
| Measurement | Meaning |
|---|---|
| 1 mg | 1,000 mcg (mass) |
| 100 U-100 units | 1 mL (volume, not dose) |
For source context, see third-party published protocols ↗. North Star does not validate these schedules.
Consult your doctor before considering any peptide for personal use. Educational only, not administration guidance.
Common questions
What is Cagrilintide?
A lab-made copy of amylin, a fullness hormone released with insulin. It is being tested alone and paired with semaglutide as "CagriSema". Your pancreas releases amylin alongside insulin after meals. It tells the brain you are full and slows the stomach. Cagrilintide is a long-acting version, and it works on a different signal than GLP-1, which is why it is being combined with semaglutide.
What does the research say about Cagrilintide?
In a 26-week trial, the top dose on its own led to about 10.8% weight loss, compared with about 3% on placebo. Combined with semaglutide (CagriSema), people in a 68-week trial lost about 20% of their body weight on average.
Is Cagrilintide FDA approved?
Not FDA-approved as of our last review. Available only inside clinical trials.
What are the side effects of Cagrilintide?
Nausea and other stomach side effects, similar to GLP-1 drugs. Research-grade products are not the tested drug and have no quality control.
Comes in these blends
- CagriSema (5/5 mg, 10/10 mg vials): Cagrilintide + Semaglutide
Related peptides
Not sure where to start?
Answer 8 quick questions and see which peptides the research points to for your goal.
Already know you want Cagrilintide? Ask Mark about it →
This page explains published research in plain language. It is not medical advice, a diagnosis, or a recommendation to take anything, and it does not give dosing. Most peptides here are not FDA-approved, and products sold online vary widely in purity. Rules around peptides are changing, so check the current status and talk with a licensed clinician before starting anything. Last reviewed 2026-10-19.